Cell No. : Cell Name
RCB2103 : 8505C
update : 2023/10/16
|
| Comment | Human cell line derived from thyroid cancer. Poorly differentiated papillary adenocarcinoma. TKG0439 (Deposited from Tohoku Univ.). |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Obinata, Masuo
|
| Originator |
Nakamura, N.
|
| Year of deposit |
2005
|
| Original cell |
TKG0439
|
| Animal |
_human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Tissue |
thyroid gland
|
| Disease name |
Poorly differentiated papillary adenocarcinoma
|
| Classification |
cancer
|
| History |
Cell Resource Center for Biomedical Research, Tohoku University（TKG0439）
|
|
Lifespan |
infinite
|
| Morphology |
epithelial-like
|
| Cellosaurus(Expasy) |
CVCL_1054
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
| Culture medium |
|
MEM + 10% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.25% Trypsin
|
Culture information
|
Passage ratio |
|
1 : 8 split
|
| SC frequency |
|
Subculture : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma |
|
(-)
|
| Isozyme |
|
LD, NP
|
| STR(human) |
|
OK
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
1
|
| User's Publication |
8
|
| User's Publication |
|
21432
Inoue M, Iizuka Y, Nakamura K, Sato GE, Mizowaki T.
Role of albumin Cys34 redox state in the progression of differentiated thyroid carcinoma and induction of ferroptosis.
Free Radic Biol Med
2023
PubMed ID: 37806598
DOI: 10.1016/j.freeradbiomed.2023.10.015
|
|
16175
Bonaldi E, Gargiuli C, De Cecco L, Micali A, Rizzetti MG, Greco A, Borrello MG, Minna E.
BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells
Int J Mol Sci
2021
22(11):5744
PubMed ID: 34072194
DOI: 10.3390/ijms22115744
|
|
20058
Aoyama M, Takizawa H, Otani T, Inoue S, Kawakita N, Tsuboi M, Bando Y, Uehara H, Kondo K, Tangoku A.
Non‑invasive monitoring of paclitaxel and lenvatinib efficacy against anaplastic thyroid cancer in orthotopic SCID mouse models using small‑animal FDG‑PET/CT.
Oncol Rep
2020
44(4):1709-1716
PubMed ID: 32945510
DOI: 10.3892/or.2020.7720
|
|
18204
Ooizumi Y, Katoh H, Yokota M, Watanabe M, Yamashita K.
Epigenetic silencing of HOPX is critically involved in aggressive phenotypes and patient prognosis in papillary thyroid cancer
Oncotarget
2019
10(57):5906-5918
PubMed ID: 31666923
DOI: 10.18632/oncotarget.27187
|
|
11296
Itai N, Shimazu T, Kimura T, Ibe I, Yamashita R, Kaburagi Y, Dohi T, Tonozuka T, Takao T, Nishikawa A.
The phosphorylation of sorting nexin 5 at serine 226 regulates retrograde transport and macropinocytosis.
PLoS ONE
2018
PubMed ID: 30419003
DOI: 10.1371/journal.pone.0207205
|
|
4466
Shimamura M, Yamamoto K, Kurashige T, Nagayama Y.
Intracellular redox status controls spherogenicity, an in vitro cancer stem cell marker, in thyroid cancer cell lines.
Exp. Cell Res.
2018
370(2):699-707
PubMed ID: 30053445
DOI: 10.1016/j.yexcr.2018.07.036
|
|
12914
Nambu J, Kobayashi T, Hashimoto M, Tashiro H, Sugino K, Shimamoto F, Kikuchi A, Ohdan H.
h-prune affects anaplastic thyroid cancer invasion and metastasis
Oncol Rep
2016
35(6):3445-52
PubMed ID: 27109060
DOI: 10.3892/or.2016.4759
|
|
7971
Sato A, Kudo C, Yamakoshi H, Uehara Y, Ohori H, Ishioka C, Iwabuchi Y, Shibata H.
Curcumin analog GO-Y030 is a novel inhibitor of IKKβ that suppresses NF-κB signaling and induces apoptosis.
Cancer Sci.
2011
102:1045-51
PubMed ID: 21272158
DOI: 10.1111/j.1349-7006.2011.01886.x
|
Back
Top
CELL BANK Website
